CHELMSFORD, MA, USA & NOVI, MI, USA & DÜSSELDORF, Germany & TOKYO, Japan I July 02, 2025 I Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic ...

Two oral presentations to highlight the safety, immunogenicity, and future development of AV-1959R for primary and secondary prevention of Alzheimer’s disease IRVINE, CA, USA I July 1, 2025 I Nuravax ...

MADRID, Spain I July 2, 2025 I mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the ...

Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties ...

ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR ...